CoChat

Atypical hypnotic compound ML297 restores sleep architecture immediately following emotionally valenced learning, to promote memory consolidation and hippocampal network activation during recall

Open access

The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.

Abstract

Sleep plays a critical role in consolidating many forms of hippocampus-dependent memory. While various classes of hypnotic drugs have been developed in recent years, it remains unknown whether, or how, some of them affect sleep-dependent memory consolidation mechanisms. We find that ML297, a recently developed candidate hypnotic agent targeting a new mechanism (activating GIRK1/2-subunit containing G-protein coupled inwardly rectifying potassium [GIRK] channels), alters sleep architecture in mice over the first 6 hr following a single-trial learning event. Following contextual fear conditioning (CFC), ML297 reversed post-CFC reductions in NREM sleep spindle power and REM sleep amounts and architecture, renormalizing sleep features to what was observed at baseline, prior to CFC. Renormalization of post-CFC REM sleep latency, REM sleep amounts, and NREM spindle power were all associated with improved contextual fear memory (CFM) consolidation. We find that improvements in CFM consolidation due to ML297 are sleep-dependent, and are associated with increased numbers of highly activated dentate gyrus (DG), CA1, and CA3 neurons during CFM recall. Together our findings suggest that GIRK1/2 channel activation restores normal sleep architecture— including REM sleep, which is normally suppressed following CFC—and increases the number of hippocampal neurons incorporated into the CFM engram during memory consolidation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/sleep/zsac301

Cites

77 of 77 references verified0 citation errors · 0 not checkable

Statistics

Figures

Graphical Abstract
Graphical Abstract CC BY · PubMed Central
Figure 1. GIRK1/2 activation restores REM sleep amounts during the first few hours of fear memory consolidation and improves fear memory recall. (A) Configuration of EEG electrodes for sleep recording and schematic of experimental design. Mice were recorded over a 24-hr baseline starting at lights-on (ZT0), then underwent single-trial contextual fear conditioning (CFC) followed by an i.p. injection of vehicle or GIRK1/2 activator ML297 (30 mg/kg). Each mouse was recorded for an additional 24 hr prior to being tested for contextual fear memory (CFM). (B) During CFC training mice in the two groups displayed similar freezing behavior. During CFM testing, freezing behavior was significantly greater in ML297-treated mice. Bars indicate mean ± SEM; n = 6 mice/group; * indicates p = 0.0141 (total freezing during recall), * indicates p = 0.0101 (change in freezing from the pre-shock period during CFC), two-tailed, unpaired t-test. (C) NREM and (D) REM sleep behavior during baseline across the light: dark cycle for vehicle- and ML297-treated mice. Shaded areas represent lights off. No changes were seen in time spent in NREM or REM sleep across the light: dark cycle nor in total NREM or REM sleep across 6 hr quartiles. n = 6 mice/group. (E–F) Sleep behavior post-conditioning across the light: dark cycle for vehicle- and ML297-treated mice. Shaded areas represent lights off. No changes were seen in time spent in NREM across the light: dark cycle. Time spent in REM sleep was significantly altered during the light cycle. REM sleep is significantly increased 3–4 hrs post-treatment of ML297 compared to vehicle controls at this same time point. Values indicate mean ± SEM; n = 6 mice/group; ** indicates p = 0.0057, Sidak’s post hoc test vs. vehicle. ML297 reorganized sleep to show significantly more total REM sleep during ZT0-6 and significantly less total REM sleep during ZT6-12. Sidak’s post hoc test vs. vehicle. * indicates p = 0.0226 (ZT0-6) and p = 0.0045 (ZT6-12), Sidak’s post hoc test vs. vehicle. (G) Compared to baseline, REM sleep in the first 6 hr post-CFC was more suppressed in vehicle-treated vs. ML297-treated mice, while significantly promoted during the last 6 hr post-CFC. *** and * indicates p = 0.0004 (ZT0-6) and p = 0.0169 (ZT6-12), respectively, Sidak’s post hoc test vs. vehicle. (H) Correlation between freezing behavior and % time spent in REM sleep in the first 6 hr post-CFC and last 6 hr post-CFC of the light cycle. R and P values are shown for Pearson correlation.
Figure 1. GIRK1/2 activation restores REM sleep amounts during the first few hours of fear memory consolidation and improves fear memory recall. (A) Configuration of EEG electrodes for sleep recording and schematic of experimental design. Mice were recorded over a 24-hr baseline starting at lights-on (ZT0), then underwent single-trial contextual fear conditioning (CFC) followed by an i.p. injection of vehicle or GIRK1/2 activator ML297 (30 mg/kg). Each mouse was recorded for an additional 24 hr prior to being tested for contextual fear memory (CFM). (B) During CFC training mice in the two groups displayed similar freezing behavior. During CFM testing, freezing behavior was significantly greater in ML297-treated mice. Bars indicate mean ± SEM; n = 6 mice/group; * indicates p = 0.0141 (total freezing during recall), * indicates p = 0.0101 (change in freezing from the pre-shock period during CFC), two-tailed, unpaired t-test. (C) NREM and (D) REM sleep behavior during baseline across the light: dark cycle for vehicle- and ML297-treated mice. Shaded areas represent lights off. No changes were seen in time spent in NREM or REM sleep across the light: dark cycle nor in total NREM or REM sleep across 6 hr quartiles. n = 6 mice/group. (E–F) Sleep behavior post-conditioning across the light: dark cycle for vehicle- and ML297-treated mice. Shaded areas represent lights off. No changes were seen in time spent in NREM across the light: dark cycle. Time spent in REM sleep was significantly altered during the light cycle. REM sleep is significantly increased 3–4 hrs post-treatment of ML297 compared to vehicle controls at this same time point. Values indicate mean ± SEM; n = 6 mice/group; ** indicates p = 0.0057, Sidak’s post hoc test vs. vehicle. ML297 reorganized sleep to show significantly more total REM sleep during ZT0-6 and significantly less total REM sleep during ZT6-12. Sidak’s post hoc test vs. vehicle. * indicates p = 0.0226 (ZT0-6) and p = 0.0045 (ZT6-12), Sidak’s post hoc test vs. vehicle. (G) Compared to baseline, REM sleep in the first 6 hr post-CFC was more suppressed in vehicle-treated vs. ML297-treated mice, while significantly promoted during the last 6 hr post-CFC. *** and * indicates p = 0.0004 (ZT0-6) and p = 0.0169 (ZT6-12), respectively, Sidak’s post hoc test vs. vehicle. (H) Correlation between freezing behavior and % time spent in REM sleep in the first 6 hr post-CFC and last 6 hr post-CFC of the light cycle. R and P values are shown for Pearson correlation.CC BY · PubMed Central
Figure 2. ML297 REM sleep architecture is promoted during post-conditioning with GIRK channel activation. (A) Mean bout duration and (B) number of bouts for NREM sleep over the 24 hr during baseline in the vehicle and ML297 groups were similar. (C) Mean bout duration and (D) number of bouts for NREM sleep over the 24 hr post-CFC in vehicle- and ML297-treated mice were similar. (E) Mean bout duration and (F) bout numbers for REM sleep over the 24 hr during baseline in the vehicle and ML297 groups were similar. (G) Mean bout duration and (H) bout numbers for REM sleep over the 24 hr post-CFC in vehicle- and ML297 treated mice. * indicates p = 0.0400 (REM bout duration), p = 0.0177 (number of REM bouts), Sidak’s post hoc test vs. vehicle. Values indicate mean ± SEM. (G) REM mean bout durations and (H) bout numbers are shown for hours 0–6 and 6–12 post-CFC. ML297-treated mice show longer REM bout durations during ZT0-6. ** indicates p = 0.0003, Sidak’s post hoc test vs. vehicle. ML297-treated mice show a greater number of REM sleep bouts during ZT0-6 and a reduced number of REM sleep bouts during ZT6-12. * indicates p = 0.0267 (ZT0-6), p = 0.0123 (ZT6-12), Sidak’s post hoc test vs. vehicle. (I) Post-CFC changes in REM mean bout duration (left) and number (right) from time-matched baseline values. ML297 administration led to a relative increase in the number of REM sleep bouts in the first 6 hr post-CFC, and a decrease in bouts in the last half of the light cycle. ** indicates p = 0.0019 (ZT0-6) and * indicates p = 0.0419 (ZT6-12), Sidak’s post hoc test vs. vehicle. (J) ML297-treated mice showed decreased latency to REM sleep (but unchanged latency to NREM sleep) after CFC (*** indicates p = 0.0001, Sidak’s post hoc test vs. vehicle). Shorter REM latency predicted successful CFM consolidation. R and P values are shown for Pearson correlation. n = 6 mice/group.
Figure 2. ML297 REM sleep architecture is promoted during post-conditioning with GIRK channel activation. (A) Mean bout duration and (B) number of bouts for NREM sleep over the 24 hr during baseline in the vehicle and ML297 groups were similar. (C) Mean bout duration and (D) number of bouts for NREM sleep over the 24 hr post-CFC in vehicle- and ML297-treated mice were similar. (E) Mean bout duration and (F) bout numbers for REM sleep over the 24 hr during baseline in the vehicle and ML297 groups were similar. (G) Mean bout duration and (H) bout numbers for REM sleep over the 24 hr post-CFC in vehicle- and ML297 treated mice. * indicates p = 0.0400 (REM bout duration), p = 0.0177 (number of REM bouts), Sidak’s post hoc test vs. vehicle. Values indicate mean ± SEM. (G) REM mean bout durations and (H) bout numbers are shown for hours 0–6 and 6–12 post-CFC. ML297-treated mice show longer REM bout durations during ZT0-6. ** indicates p = 0.0003, Sidak’s post hoc test vs. vehicle. ML297-treated mice show a greater number of REM sleep bouts during ZT0-6 and a reduced number of REM sleep bouts during ZT6-12. * indicates p = 0.0267 (ZT0-6), p = 0.0123 (ZT6-12), Sidak’s post hoc test vs. vehicle. (I) Post-CFC changes in REM mean bout duration (left) and number (right) from time-matched baseline values. ML297 administration led to a relative increase in the number of REM sleep bouts in the first 6 hr post-CFC, and a decrease in bouts in the last half of the light cycle. ** indicates p = 0.0019 (ZT0-6) and * indicates p = 0.0419 (ZT6-12), Sidak’s post hoc test vs. vehicle. (J) ML297-treated mice showed decreased latency to REM sleep (but unchanged latency to NREM sleep) after CFC (*** indicates p = 0.0001, Sidak’s post hoc test vs. vehicle). Shorter REM latency predicted successful CFM consolidation. R and P values are shown for Pearson correlation. n = 6 mice/group.CC BY · PubMed Central
Figure 3. ML297 has modest effects on overall NREM and REM EEG spectral power. EEG power spectra (recorded over visual cortex, bilaterally) are shown for vehicle- and ML297-treated mice during NREM baseline (A) and post-CFC (B), and during REM baseline (C) and post-CFC (D). Values indicate % of total spectral power at each frequency band, mean ± SEM; n = 6 mice/group. For (B), **** and * indicate post-CFC differences in NREM delta frequency bands at ZT0-6 and 6-12, respectively, p ≤ 0.0001 for 2.9–3.9 Hz, and p < 0.05 for 1.4–1.7 Hz, respectively, Sidak’s post hoc test vs. vehicle. For (D), *** indicates post-CFC differences in REM at ZT2-6, p < 0.001 for 7.1–8.1 Hz, Sidak’s post hoc test vs. vehicle. Values indicate mean ± SEM; n = 6 mice/group. (E) Comparisons of changes in spectral power from baseline showed significant differences in NREM delta frequency bands from 0.7–1.9 and 2.9−–3.9 Hz (p < 0.0001, Sidak’s post hoc test) at ZT0-6 and REM theta frequency bands 6.8–8.3 Hz (p < 0.0001, Sidak’s post hoc test) at ZT2-6. (F) Over the following 6 hr of the light phase (ZT6-12) no changes in spectral power from baseline were observed in either NREM or REM.
Figure 3. ML297 has modest effects on overall NREM and REM EEG spectral power. EEG power spectra (recorded over visual cortex, bilaterally) are shown for vehicle- and ML297-treated mice during NREM baseline (A) and post-CFC (B), and during REM baseline (C) and post-CFC (D). Values indicate % of total spectral power at each frequency band, mean ± SEM; n = 6 mice/group. For (B), **** and * indicate post-CFC differences in NREM delta frequency bands at ZT0-6 and 6-12, respectively, p ≤ 0.0001 for 2.9–3.9 Hz, and p < 0.05 for 1.4–1.7 Hz, respectively, Sidak’s post hoc test vs. vehicle. For (D), *** indicates post-CFC differences in REM at ZT2-6, p < 0.001 for 7.1–8.1 Hz, Sidak’s post hoc test vs. vehicle. Values indicate mean ± SEM; n = 6 mice/group. (E) Comparisons of changes in spectral power from baseline showed significant differences in NREM delta frequency bands from 0.7–1.9 and 2.9−–3.9 Hz (p < 0.0001, Sidak’s post hoc test) at ZT0-6 and REM theta frequency bands 6.8–8.3 Hz (p < 0.0001, Sidak’s post hoc test) at ZT2-6. (F) Over the following 6 hr of the light phase (ZT6-12) no changes in spectral power from baseline were observed in either NREM or REM.CC BY · PubMed Central
Figure 4. ML297 normalizes NREM sleep spindle power in the hours following CFC. NREM spindle density (A) and mean duration (B) were similar between vehicle and ML297 groups for hours 0–12 during baseline. (C) NREM EEG spectral power within the spindle/sigma frequency band (7–15 Hz) was similar between groups at baseline. NREM spindle density (D) and mean duration (E) were similar between both vehicle- and ML297-treated mice following CFC. (F) Over the first 4 hr following CFC, NREM spindle power was higher in ML297-treated mice relative to vehicle-treated mice. * indicates p < 0.05, Sidak’s post hoc test. Values indicate mean ± SEM; n = 6 mice/group.
Figure 4. ML297 normalizes NREM sleep spindle power in the hours following CFC. NREM spindle density (A) and mean duration (B) were similar between vehicle and ML297 groups for hours 0–12 during baseline. (C) NREM EEG spectral power within the spindle/sigma frequency band (7–15 Hz) was similar between groups at baseline. NREM spindle density (D) and mean duration (E) were similar between both vehicle- and ML297-treated mice following CFC. (F) Over the first 4 hr following CFC, NREM spindle power was higher in ML297-treated mice relative to vehicle-treated mice. * indicates p < 0.05, Sidak’s post hoc test. Values indicate mean ± SEM; n = 6 mice/group.CC BY · PubMed Central
Figure 5. Post-CFC ML297 administration improves CFM consolidation in a sleep-dependent manner. (A) Experimental design. Mice underwent single-trial CFC at lights on, were subsequentially administered vehicle or ML297 (30 mg/kg) via i.p. injection and returned to their home cage. Mice in the two drug treatment groups were then allowed ad lib sleep or were sleep deprived over the first 6 hr post-CFC, after which all mice were allowed to sleep freely in their home cage until CFM testing the following day at lights on. (B) Total amounts of observed sleep during the first 6 hr post-CFC were similar for the two ad lib sleep groups. Bars indicate mean ± SEM, n = 5 and 6 mice, respectively, for vehicle and ML297. (C) Vehicle and ML297 groups in both ad lib sleep and sleep deprivation (SD) conditions had similar freezing behavior during training (pre-shock and post-shock). n = 5 and 6 mice, respectively, for vehicle and ML297 groups with ad lib sleep, and n = 7 and 6 mice, respectively, for vehicle and ML297 groups with SD. Freezing behavior during recall, and changes in freezing from the CFC pre-shock period, were significantly greater in freely sleeping ML297-treated mice compared with freely sleeping vehicle-treated mice. SD reduced CFM-associated freezing behavior in both treatment groups, which did not differ from one another. n = 5 and 6 mice, respectively, for vehicle and ML297 with ad lib sleep, and n = 7 and 6 mice, respectively, for vehicle and ML297 with SD. *, **, *** and **** indicate p < 0.05, p < 0.01, p < 0.001, and p < 0.0001, respectively, Tukey’s post hoc test.
Figure 5. Post-CFC ML297 administration improves CFM consolidation in a sleep-dependent manner. (A) Experimental design. Mice underwent single-trial CFC at lights on, were subsequentially administered vehicle or ML297 (30 mg/kg) via i.p. injection and returned to their home cage. Mice in the two drug treatment groups were then allowed ad lib sleep or were sleep deprived over the first 6 hr post-CFC, after which all mice were allowed to sleep freely in their home cage until CFM testing the following day at lights on. (B) Total amounts of observed sleep during the first 6 hr post-CFC were similar for the two ad lib sleep groups. Bars indicate mean ± SEM, n = 5 and 6 mice, respectively, for vehicle and ML297. (C) Vehicle and ML297 groups in both ad lib sleep and sleep deprivation (SD) conditions had similar freezing behavior during training (pre-shock and post-shock). n = 5 and 6 mice, respectively, for vehicle and ML297 groups with ad lib sleep, and n = 7 and 6 mice, respectively, for vehicle and ML297 groups with SD. Freezing behavior during recall, and changes in freezing from the CFC pre-shock period, were significantly greater in freely sleeping ML297-treated mice compared with freely sleeping vehicle-treated mice. SD reduced CFM-associated freezing behavior in both treatment groups, which did not differ from one another. n = 5 and 6 mice, respectively, for vehicle and ML297 with ad lib sleep, and n = 7 and 6 mice, respectively, for vehicle and ML297 with SD. *, **, *** and **** indicate p < 0.05, p < 0.01, p < 0.001, and p < 0.0001, respectively, Tukey’s post hoc test.CC BY · PubMed Central
Figure 6. Post-CFC ML297 increases the number of active neurons in DG during subsequent CFM recall, in a sleep-dependent manner. (A) Experimental paradigm. Mice underwent single-trial CFC, were administered vehicle or ML297 (30 mg/kg) following training, and then were either allowed ad lib sleep or underwent 6-hr sleep deprivation (SD). 24 hr after CFC, mice were tested for CFM, and perfused 90 min later to immunohistochemically quantify recall-associated cFos and Arc IEG expression in dorsal hippocampus. n = 5 mice/ group. (B) Representative images of cFos+ and Arc+ DG neurons following CFM recall in the four treatment groups. Scale bar = 100 µm. (C) Mice allowed ad lib sleep had significantly increased cFos+ neuron counts across DG compared to both SD groups. ML297 increased cFos+ neuron numbers further in freely sleeping mice. Similar patterns were observed for the two DG granule cell blades, and for the DG hilus. (D) Arc+ neuron counts across DG were also reduced in both SD groups. ML297 administration led to a trend for higher overall Arc+ DG neurons relative to vehicles in freely sleeping mice. *, **, ***, and **** indicate p < 0.05, p < 0.01, p < 0.001, and p < 0.0001, respectively, Sidak’s post hoc test. (E) Higher numbers of cFos+ and Arc+ neurons across DG at recall reflected the success of CFM consolidation across individual mice. R and P values are shown for Pearson correlation.
Figure 6. Post-CFC ML297 increases the number of active neurons in DG during subsequent CFM recall, in a sleep-dependent manner. (A) Experimental paradigm. Mice underwent single-trial CFC, were administered vehicle or ML297 (30 mg/kg) following training, and then were either allowed ad lib sleep or underwent 6-hr sleep deprivation (SD). 24 hr after CFC, mice were tested for CFM, and perfused 90 min later to immunohistochemically quantify recall-associated cFos and Arc IEG expression in dorsal hippocampus. n = 5 mice/ group. (B) Representative images of cFos+ and Arc+ DG neurons following CFM recall in the four treatment groups. Scale bar = 100 µm. (C) Mice allowed ad lib sleep had significantly increased cFos+ neuron counts across DG compared to both SD groups. ML297 increased cFos+ neuron numbers further in freely sleeping mice. Similar patterns were observed for the two DG granule cell blades, and for the DG hilus. (D) Arc+ neuron counts across DG were also reduced in both SD groups. ML297 administration led to a trend for higher overall Arc+ DG neurons relative to vehicles in freely sleeping mice. *, **, ***, and **** indicate p < 0.05, p < 0.01, p < 0.001, and p < 0.0001, respectively, Sidak’s post hoc test. (E) Higher numbers of cFos+ and Arc+ neurons across DG at recall reflected the success of CFM consolidation across individual mice. R and P values are shown for Pearson correlation.CC BY · PubMed Central
Figure 7. Post-CFC ML297 increases the number of active neurons in CA1 during subsequent CFM recall, in a sleep-independent manner. (A) Experimental design, as in Figure 6A. (B) Representative images of cFos+ neurons and Arc+ mean fluorescence intensity (MFI) in the pyramidal layers in CA1 and CA3 following CFM recall in the four groups. Scale bar = 100 µm. (C) Post-CFC sleep deprivation (SD) significantly decreased the number of cFos+ neurons in CA1 and CA3 during recall in vehicle-treated mice. In CA1 only, ML297 increased cFos+ neuron numbers after recall in SD mice as well as freely sleeping mice. No significant changes in Arc MFI were observed with SD or drug treatment in either CA1 or CA3. *, **, and *** indicate p < 0.05, p < 0.01, and p < 0.001, respectively, Sidak’s post hoc test. (D) Numbers of cFos+ neurons in both CA1 and CA3 during recall correlated with CFM recall performance. No correlations were observed between freezing behavior and Arc MFI expression. R and P values are shown for Pearson correlation.
Figure 7. Post-CFC ML297 increases the number of active neurons in CA1 during subsequent CFM recall, in a sleep-independent manner. (A) Experimental design, as in Figure 6A. (B) Representative images of cFos+ neurons and Arc+ mean fluorescence intensity (MFI) in the pyramidal layers in CA1 and CA3 following CFM recall in the four groups. Scale bar = 100 µm. (C) Post-CFC sleep deprivation (SD) significantly decreased the number of cFos+ neurons in CA1 and CA3 during recall in vehicle-treated mice. In CA1 only, ML297 increased cFos+ neuron numbers after recall in SD mice as well as freely sleeping mice. No significant changes in Arc MFI were observed with SD or drug treatment in either CA1 or CA3. *, **, and *** indicate p < 0.05, p < 0.01, and p < 0.001, respectively, Sidak’s post hoc test. (D) Numbers of cFos+ neurons in both CA1 and CA3 during recall correlated with CFM recall performance. No correlations were observed between freezing behavior and Arc MFI expression. R and P values are shown for Pearson correlation.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 77 references

Cited by

See all 11

Metadata

Authors
Martinez, J. D., Brancaleone, W. P., Peterson, K. G., Wilson, L. G., & Aton, S. J.
Affiliations
University of Michigan (US)
Corresponding author
Aton, Sara J
Venue
Sleep
Published
2022-12-13
Volume
46
Issue
3
ISSN
  • 0161-8105 (ISSN-L)
  • 1550-9109
OpenAlex
W4311282554
Cited by
11
References
77
Citations by year
2026: 4 · 2025: 2 · 2024: 3 · 2023: 2
FWCI
0.90
Type
journal article
Language
en
Open access
Locations
  • SLEEP (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
National Institutes of Health (R01 NS104776, RF1 NS118440)
Topics
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Sleep and Wakefulness Research
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Memory and Neural Mechanisms
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Neuroscience of respiration and sleep
Keywords
hypnotics, sleep architecture, memory consolidation, contextual fear memory, REM sleep, GIRK channels, dentate gyrus, CA1, CA3, sleep-dependent memory
MeSH terms
Memory Consolidation, Animals, Hippocampus, Hypnotics and Sedatives, Learning, Sleep, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Atypical hypnotic compound ML297 restores sleep architecture immediately following emotionally valenced learning, to promote memory consolidation and hippocampal network activation during recall. https://app.cochat.ai/papers/10.1093/sleep/zsac301
The paper
Martinez, J. D., Brancaleone, W. P., Peterson, K. G., Wilson, L. G., & Aton, S. J. (2023). Atypical hypnotic compound ML297 restores sleep architecture immediately following emotionally valenced learning, to promote memory consolidation and hippocampal network activation during recall. Sleep. https://doi.org/10.1093/sleep/zsac301

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.